No influence of prednisolone on IGFBP-3 proteolysis in healthy young men

Hormone Research

Volumn 55, Issue 2, 2001, Pages 95-101

  Dall, Rolf ^a   Wolthers, Troels ^a   Flyvbjerg, Allan ^a,b   Grøfte, Thorbjørn ^a   Christiansen, Jens Sandahl ^a   Jørgensen, Jens Otto ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

Glucocorticoid; IGFBP 3 proteolysis; Insulin like growth factor binding proteins; Insulin like growth factor I; Western ligand blotting

Indexed keywords

GROWTH HORMONE; PREDNISOLONE; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ARTICLE; DRUG EFFECT; DRUG MECHANISM; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; WESTERN BLOTTING;

ADULT; BLOTTING, WESTERN; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; HUMAN GROWTH HORMONE; HUMANS; IMMUNOASSAY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MALE; PLACEBOS; PREDNISOLONE;

EID: 0034880459     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000049977     Document Type: Article

References (46)

1. Human growth hormone prevents the protein catabolic side effects of prednisone in humans
2. Effects of growth hormone and IGF-I on glucocorticoid-induced protein catabolism in humans
3. Growth hormone prevents prednisolone-induced increase in functional hepatic nitrogen clearance in normal man
4. Growth hormone and lean tissue catabolism during long-term glucocorticoid treatment
5. Effects of dexamethasone on growth hormone (GH)-releasing hormone, arginine- and dopaminergic stimulated GH secretion, and total plasma insulin-like growth factor-I concentrations in normal male volunteers
6. Dual and selective actions of glucocorticoids upon basal and stimulated growth hormone release in man
7. Inhibition by prednisone of growth hormone (GH) response to GH-releasing hormone in normal men
8. Estimation of somatomedin-C levels in normals and patients with pituitary disease by radioimmunoassay
9. Insulin-like growth factor 1 and bone turnover in glucocorticoid-treated and control subjects
10. Glucocorticoid effects on somatomedins and somatomedin inhibitors
11. Dexamethasone treatment in man induces changes in 24-hour growth hormone (GH) secretion profile without altering total GH released
12. The effects of dexamethasone treatment on immunoreactive and bioactive insulin-like growth factors (IGFs) and IGF-binding proteins in normal male volunteers
13. Insulin-like growth factor (IGF) I and II and IGF binding protein (IGFBP) 1, 2 and 3 in serum from patients with Cushing's syndrome
14. Divergent effects of short-term glucocorticoid excess on the gonadotropic and somatotropic axes in normal men
15. The effect of long-term prednisone treatment on growth hormone and insulin-like growth factor-1
16. The evolution of changes in immunoreactive serum insulin-like growth factors (IGFs), IGF-binding proteins, circulating growth hormone (GH) and GH-binding protein as a result of short-term dexamethasone treatment
17. The effect of recombinant human growth hormone on glucose and leucine metabolism in Cushing's syndrome
18. The insulin-like growth factor axis and collagen turnover during prednisolone treatment
19. Glucocorticoid therapy in children. Effect on somatomedin secretion
20. Plasma levels, half-life values, and correlation with physiologic assays for growth and immunity
21. Insulin-like growth factor-binding protein proteolysis
22. Non-competitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II
23. Analysis of serum insulin-like growth factor binding proteins using western blotting: Use of the method for titration of the binding proteins and competitive binding studies
24. Transient increase in renal insulin-like growth factor binding proteins during initial kidney hypertrophy in experimental diabetes in rats
25. A simple assay for proteolysis of IGFBP-3
26. Corticoid-induced growth hormone (GH) secretion in GH-deficient and normal children
27. Dexamethasone impairs growth hormone (GH)-stimulated growth by suppression of local insulin-like growth factor (IGF)-I production and expression of GH-and IGF-I-receptor in cultured rat chondrocytes
28. Cortisol inhibits the synthesis of insulin-like growth factor-I in skeletal cells
29. Glucocorticoids and muscle catabolism
30. Evidence of enzymatic degradation of insulin-like growth factor-binding proteins in the 150K complex during pregnancy
31. The induction of specific proteases for insulin-like growth factor-binding proteins following major heart surgery
32. Insulin-like growth factor-binding protein-3 proteolysis is induced after elective surgery
33. Insulin-like growth factor binding protein (IGFBP)-3 protease activity secreted by MCF-7 breast cancer cells: Inhibition by IGFs does not require IGF-IGFBP interaction
34. Differential changes in free and total insulin-like growth factor I after major, elective abdominal surgery: The possible role of insulin-like growth factor-binding protein-3 proteolysis
35. Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3)
36. In vivo proteolysis of serum insulin-like growth factor (IGF) binding protein-3 results in increased availability of IGF to target cells
37. The pharmacokinetics of free insulin-like growth factor-I in healthy subjects
38. A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin
39. No effect of growth hormone on serum insulin-like growth factor binding protein-3 proteolysis
40. The insulin-like growth factor binding protein-1 in low and high insulin responders before and during dexamethasone treatment
41. Cortisol increases plasma insulin-like growth factor binding protein-1 in humans
42. Dexamethasone increases hepatic insulin-like growth factor binding protein-1 (IGFBP-1) mRNA and serum IGFBP-1 concentrations in the rat
43. The acidlabile subunit of human ternary insulin-like growth factor binding protein complex in serum: Hepatosplanchnic release, diurnal variation, circulating concentrations in healthy subjects, and diagnostic use in patients with growth hormone deficiency
44. Insulin-like growth factors (IGF) I and II and IGF binding proteins 1, 2 and 3 during low-dose growth hormone (GH) infusion and sequential euglycemic and hypoglycemic glucose clamps: Studies in GH-deficient patients
45. The effect of four weeks of supraphysiological growth hormone administration on the insulin-like growth factor axis in women and men
46. Clinical studies of IGFBP-2 by radioimmunoassay